Decibel obtains exclusive license to commercialize ORC-13661 for preventing hearing, balance disorders

Decibel Therapeutics and Oricula Therapeutics today announced that Decibel has obtained an exclusive, worldwide license to the development and commercialization of ORC-13661, an oral medication developed by Oricula Therapeutics for the prevention of hearing loss and balance disorders that can occur following treatment of severe infections with aminoglycoside antibiotics. Particularly susceptible populations include those treated for pulmonary exacerbations associated with cystic fibrosis, non-tuberculous mycobacterial infections, multidrug-resistant tuberculosis, and endocarditis. As part of the agreement, Oricula will provide ongoing scientific advice and support.

"Aminoglycosides are an important class of antibiotics that offer powerful efficacy for serious infections," said Oricula CEO Malcolm Gleser, M.D., Ph.D. "With that efficacy, however, comes the risk of permanent hearing loss and balance problems, which can have a significant impact on quality of life. This is especially true for cystic fibrosis patients, who often require repeat courses of aminoglycosides to treat pulmonary exacerbations throughout their life. We are thrilled to partner with Decibel to bring this much-needed medication to clinicians and patients."

With roots in a research collaboration between the University of Washington and the Fred Hutchinson Cancer Research Center, ORC-13661 was licensed to Oricula Therapeutics in 2013 to accelerate preclinical research activities and advance the compound into the clinic. A Phase I clinical trial to evaluate safety, tolerability and pharmacokinetics is currently ongoing.

"Decibel has built the first fully integrated discovery, development, and translational platform tailor-made for hearing therapeutics. Our specialized capabilities in hearing have increasingly led world-class hearing researchers like the team at Oricula to seek out partnerships with Decibel," noted Paula Cobb, EVP Corporate Development at Decibel. "We are eager to apply our expertise and resources to the development of a novel medicine addressing a significant unmet need. Clinicians and patients should not have to sacrifice hearing and balance to achieve the potent antibiotic efficacy of aminoglycosides."


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study reveals inflammation's role in long COVID's lingering effects